Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE)

use of a unique community and laboratory national data-linked cohort study

Colin R Simpson, Nazir Lone, Jim McMenamin, Rory Gunson, Chris Robertson, Lewis D Ritchie, Aziz Sheikh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: After the introduction of any new pandemic influenza, population-level surveillance and rapid assessment of the effectiveness of a new vaccination will be required to ensure that it is targeted to those at increased risk of serious illness or death from influenza.

OBJECTIVE: We aimed to build a pandemic influenza reporting platform that will determine, once a new pandemic is under way: the uptake and effectiveness of any new pandemic vaccine or any protective effect conferred by antiviral drugs once available; the clinical attack rate of pandemic influenza; and the existence of protection provided by previous exposure to, and vaccination from, A/H1N1 pandemic or seasonal influenza/identification of susceptible groups.

DESIGN: An observational cohort and test-negative study design will be used (post pandemic).

SETTING: A national linkage of patient-level general practice data from 41 Practice Team Information general practices, hospitalisation and death certification, virological swab and serology-linked data.

PARTICIPANTS: We will study a nationally representative sample of the Scottish population comprising 300,000 patients. Confirmation of influenza using reverse transcription polymerase chain reaction and, in a subset of the population, serology.

INTERVENTIONS: Future available pandemic influenza vaccination and antivirals will be evaluated.

MAIN OUTCOME MEASURES: To build a reporting platform tailored towards the evaluation of pandemic influenza vaccination. This system will rapidly measure vaccine effectiveness (VE), adjusting for confounders, estimated by determining laboratory-confirmed influenza; influenza-related morbidity and mortality, including general practice influenza-like illnesses (ILIs); and hospitalisation and death from influenza and pneumonia. Once a validated haemagglutination inhibition assay has been developed (and prior to the introduction of any vaccination), cross-reactivity with previous exposure to A/H1N1 or A/H1N1 vaccination, other pandemic influenza or other seasonal influenza vaccination or exposure will be measured.

CONCLUSIONS: A new sentinel system, capable of rapidly determining the estimated incidence of pandemic influenza, and pandemic influenza vaccine and antiviral uptake and effectiveness in preventing influenza and influenza-related clinical outcomes, has been created. We have all of the required regulatory approvals to allow rapid activation of the sentinel systems in the event of a pandemic. Of the 41 practices expressing an interest in participating, 40 have completed all of the necessary paperwork to take part in the reporting platform. The data extraction tool has been installed in these practices. Data extraction and deterministic linkage systems have been tested. Four biochemistry laboratories have been recruited, and systems for serology collection and linkage of samples to general practice data have been put in place.

FUTURE WORK: The reporting platform has been set up and is ready to be activated in the event of any pandemic of influenza. Building on this infrastructure, there is now the opportunity to extend the network of general practices to allow important subgroup analyses of VE (e.g. for patients with comorbidities, at risk of serious ILI) and to link to other data sources, in particular to test for maternal outcomes in pregnant patients.

STUDY REGISTRATION: This study is registered as ISRCTN55398410.

FUNDING: The National Institute for Health Research Health Technology Assessment programme.

Original languageEnglish
Pages (from-to)1-32
Number of pages32
JournalHealth Technology Assessment
Volume19
Issue number79
DOIs
Publication statusPublished - Oct 2015

Fingerprint

Influenza Vaccines
Pandemics
Human Influenza
Antiviral Agents
Cohort Studies
Vaccination
General Practice
Serology
Vaccines
Hospitalization
Population Surveillance
Biomedical Technology Assessment
Social Identification
Information Storage and Retrieval
Certification
National Institutes of Health (U.S.)

Keywords

  • Antiviral Agents
  • Cohort Studies
  • Data Collection
  • Female
  • Hemagglutination Inhibition Tests
  • Hospitalization
  • Humans
  • Incidence
  • Influenza A Virus, H1N1 Subtype
  • Influenza Vaccines
  • Influenza, Human
  • Male
  • Outcome Assessment (Health Care)
  • Pandemics
  • Pregnancy
  • Residence Characteristics
  • Scotland
  • Sentinel Surveillance
  • Journal Article
  • Observational Study
  • Research Support, Non-U.S. Gov't

Cite this

Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE) : use of a unique community and laboratory national data-linked cohort study. / Simpson, Colin R; Lone, Nazir; McMenamin, Jim; Gunson, Rory; Robertson, Chris; Ritchie, Lewis D; Sheikh, Aziz.

In: Health Technology Assessment, Vol. 19, No. 79, 10.2015, p. 1-32.

Research output: Contribution to journalArticle

Simpson, Colin R ; Lone, Nazir ; McMenamin, Jim ; Gunson, Rory ; Robertson, Chris ; Ritchie, Lewis D ; Sheikh, Aziz. / Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE) : use of a unique community and laboratory national data-linked cohort study. In: Health Technology Assessment. 2015 ; Vol. 19, No. 79. pp. 1-32.
@article{f6fd906c79734e00958914d7bcbf239c,
title = "Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study",
abstract = "BACKGROUND: After the introduction of any new pandemic influenza, population-level surveillance and rapid assessment of the effectiveness of a new vaccination will be required to ensure that it is targeted to those at increased risk of serious illness or death from influenza.OBJECTIVE: We aimed to build a pandemic influenza reporting platform that will determine, once a new pandemic is under way: the uptake and effectiveness of any new pandemic vaccine or any protective effect conferred by antiviral drugs once available; the clinical attack rate of pandemic influenza; and the existence of protection provided by previous exposure to, and vaccination from, A/H1N1 pandemic or seasonal influenza/identification of susceptible groups.DESIGN: An observational cohort and test-negative study design will be used (post pandemic).SETTING: A national linkage of patient-level general practice data from 41 Practice Team Information general practices, hospitalisation and death certification, virological swab and serology-linked data.PARTICIPANTS: We will study a nationally representative sample of the Scottish population comprising 300,000 patients. Confirmation of influenza using reverse transcription polymerase chain reaction and, in a subset of the population, serology.INTERVENTIONS: Future available pandemic influenza vaccination and antivirals will be evaluated.MAIN OUTCOME MEASURES: To build a reporting platform tailored towards the evaluation of pandemic influenza vaccination. This system will rapidly measure vaccine effectiveness (VE), adjusting for confounders, estimated by determining laboratory-confirmed influenza; influenza-related morbidity and mortality, including general practice influenza-like illnesses (ILIs); and hospitalisation and death from influenza and pneumonia. Once a validated haemagglutination inhibition assay has been developed (and prior to the introduction of any vaccination), cross-reactivity with previous exposure to A/H1N1 or A/H1N1 vaccination, other pandemic influenza or other seasonal influenza vaccination or exposure will be measured.CONCLUSIONS: A new sentinel system, capable of rapidly determining the estimated incidence of pandemic influenza, and pandemic influenza vaccine and antiviral uptake and effectiveness in preventing influenza and influenza-related clinical outcomes, has been created. We have all of the required regulatory approvals to allow rapid activation of the sentinel systems in the event of a pandemic. Of the 41 practices expressing an interest in participating, 40 have completed all of the necessary paperwork to take part in the reporting platform. The data extraction tool has been installed in these practices. Data extraction and deterministic linkage systems have been tested. Four biochemistry laboratories have been recruited, and systems for serology collection and linkage of samples to general practice data have been put in place.FUTURE WORK: The reporting platform has been set up and is ready to be activated in the event of any pandemic of influenza. Building on this infrastructure, there is now the opportunity to extend the network of general practices to allow important subgroup analyses of VE (e.g. for patients with comorbidities, at risk of serious ILI) and to link to other data sources, in particular to test for maternal outcomes in pregnant patients.STUDY REGISTRATION: This study is registered as ISRCTN55398410.FUNDING: The National Institute for Health Research Health Technology Assessment programme.",
keywords = "Antiviral Agents, Cohort Studies, Data Collection, Female, Hemagglutination Inhibition Tests, Hospitalization, Humans, Incidence, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human, Male, Outcome Assessment (Health Care), Pandemics, Pregnancy, Residence Characteristics, Scotland, Sentinel Surveillance, Journal Article, Observational Study, Research Support, Non-U.S. Gov't",
author = "Simpson, {Colin R} and Nazir Lone and Jim McMenamin and Rory Gunson and Chris Robertson and Ritchie, {Lewis D} and Aziz Sheikh",
note = "The authors would like to thank staff at Albasoft Ltd, HPS, WoSSVC and the Information Services Division, the general practices and biochemistry laboratories contributing data or serology to the study and members of the Independent Steering Committee overseeing this work.",
year = "2015",
month = "10",
doi = "10.3310/hta19790",
language = "English",
volume = "19",
pages = "1--32",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "National Co-ordinating Centre for HTA",
number = "79",

}

TY - JOUR

T1 - Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE)

T2 - use of a unique community and laboratory national data-linked cohort study

AU - Simpson, Colin R

AU - Lone, Nazir

AU - McMenamin, Jim

AU - Gunson, Rory

AU - Robertson, Chris

AU - Ritchie, Lewis D

AU - Sheikh, Aziz

N1 - The authors would like to thank staff at Albasoft Ltd, HPS, WoSSVC and the Information Services Division, the general practices and biochemistry laboratories contributing data or serology to the study and members of the Independent Steering Committee overseeing this work.

PY - 2015/10

Y1 - 2015/10

N2 - BACKGROUND: After the introduction of any new pandemic influenza, population-level surveillance and rapid assessment of the effectiveness of a new vaccination will be required to ensure that it is targeted to those at increased risk of serious illness or death from influenza.OBJECTIVE: We aimed to build a pandemic influenza reporting platform that will determine, once a new pandemic is under way: the uptake and effectiveness of any new pandemic vaccine or any protective effect conferred by antiviral drugs once available; the clinical attack rate of pandemic influenza; and the existence of protection provided by previous exposure to, and vaccination from, A/H1N1 pandemic or seasonal influenza/identification of susceptible groups.DESIGN: An observational cohort and test-negative study design will be used (post pandemic).SETTING: A national linkage of patient-level general practice data from 41 Practice Team Information general practices, hospitalisation and death certification, virological swab and serology-linked data.PARTICIPANTS: We will study a nationally representative sample of the Scottish population comprising 300,000 patients. Confirmation of influenza using reverse transcription polymerase chain reaction and, in a subset of the population, serology.INTERVENTIONS: Future available pandemic influenza vaccination and antivirals will be evaluated.MAIN OUTCOME MEASURES: To build a reporting platform tailored towards the evaluation of pandemic influenza vaccination. This system will rapidly measure vaccine effectiveness (VE), adjusting for confounders, estimated by determining laboratory-confirmed influenza; influenza-related morbidity and mortality, including general practice influenza-like illnesses (ILIs); and hospitalisation and death from influenza and pneumonia. Once a validated haemagglutination inhibition assay has been developed (and prior to the introduction of any vaccination), cross-reactivity with previous exposure to A/H1N1 or A/H1N1 vaccination, other pandemic influenza or other seasonal influenza vaccination or exposure will be measured.CONCLUSIONS: A new sentinel system, capable of rapidly determining the estimated incidence of pandemic influenza, and pandemic influenza vaccine and antiviral uptake and effectiveness in preventing influenza and influenza-related clinical outcomes, has been created. We have all of the required regulatory approvals to allow rapid activation of the sentinel systems in the event of a pandemic. Of the 41 practices expressing an interest in participating, 40 have completed all of the necessary paperwork to take part in the reporting platform. The data extraction tool has been installed in these practices. Data extraction and deterministic linkage systems have been tested. Four biochemistry laboratories have been recruited, and systems for serology collection and linkage of samples to general practice data have been put in place.FUTURE WORK: The reporting platform has been set up and is ready to be activated in the event of any pandemic of influenza. Building on this infrastructure, there is now the opportunity to extend the network of general practices to allow important subgroup analyses of VE (e.g. for patients with comorbidities, at risk of serious ILI) and to link to other data sources, in particular to test for maternal outcomes in pregnant patients.STUDY REGISTRATION: This study is registered as ISRCTN55398410.FUNDING: The National Institute for Health Research Health Technology Assessment programme.

AB - BACKGROUND: After the introduction of any new pandemic influenza, population-level surveillance and rapid assessment of the effectiveness of a new vaccination will be required to ensure that it is targeted to those at increased risk of serious illness or death from influenza.OBJECTIVE: We aimed to build a pandemic influenza reporting platform that will determine, once a new pandemic is under way: the uptake and effectiveness of any new pandemic vaccine or any protective effect conferred by antiviral drugs once available; the clinical attack rate of pandemic influenza; and the existence of protection provided by previous exposure to, and vaccination from, A/H1N1 pandemic or seasonal influenza/identification of susceptible groups.DESIGN: An observational cohort and test-negative study design will be used (post pandemic).SETTING: A national linkage of patient-level general practice data from 41 Practice Team Information general practices, hospitalisation and death certification, virological swab and serology-linked data.PARTICIPANTS: We will study a nationally representative sample of the Scottish population comprising 300,000 patients. Confirmation of influenza using reverse transcription polymerase chain reaction and, in a subset of the population, serology.INTERVENTIONS: Future available pandemic influenza vaccination and antivirals will be evaluated.MAIN OUTCOME MEASURES: To build a reporting platform tailored towards the evaluation of pandemic influenza vaccination. This system will rapidly measure vaccine effectiveness (VE), adjusting for confounders, estimated by determining laboratory-confirmed influenza; influenza-related morbidity and mortality, including general practice influenza-like illnesses (ILIs); and hospitalisation and death from influenza and pneumonia. Once a validated haemagglutination inhibition assay has been developed (and prior to the introduction of any vaccination), cross-reactivity with previous exposure to A/H1N1 or A/H1N1 vaccination, other pandemic influenza or other seasonal influenza vaccination or exposure will be measured.CONCLUSIONS: A new sentinel system, capable of rapidly determining the estimated incidence of pandemic influenza, and pandemic influenza vaccine and antiviral uptake and effectiveness in preventing influenza and influenza-related clinical outcomes, has been created. We have all of the required regulatory approvals to allow rapid activation of the sentinel systems in the event of a pandemic. Of the 41 practices expressing an interest in participating, 40 have completed all of the necessary paperwork to take part in the reporting platform. The data extraction tool has been installed in these practices. Data extraction and deterministic linkage systems have been tested. Four biochemistry laboratories have been recruited, and systems for serology collection and linkage of samples to general practice data have been put in place.FUTURE WORK: The reporting platform has been set up and is ready to be activated in the event of any pandemic of influenza. Building on this infrastructure, there is now the opportunity to extend the network of general practices to allow important subgroup analyses of VE (e.g. for patients with comorbidities, at risk of serious ILI) and to link to other data sources, in particular to test for maternal outcomes in pregnant patients.STUDY REGISTRATION: This study is registered as ISRCTN55398410.FUNDING: The National Institute for Health Research Health Technology Assessment programme.

KW - Antiviral Agents

KW - Cohort Studies

KW - Data Collection

KW - Female

KW - Hemagglutination Inhibition Tests

KW - Hospitalization

KW - Humans

KW - Incidence

KW - Influenza A Virus, H1N1 Subtype

KW - Influenza Vaccines

KW - Influenza, Human

KW - Male

KW - Outcome Assessment (Health Care)

KW - Pandemics

KW - Pregnancy

KW - Residence Characteristics

KW - Scotland

KW - Sentinel Surveillance

KW - Journal Article

KW - Observational Study

KW - Research Support, Non-U.S. Gov't

U2 - 10.3310/hta19790

DO - 10.3310/hta19790

M3 - Article

VL - 19

SP - 1

EP - 32

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 79

ER -